홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

1-(Cyclopropylmethyl)piperazine → 4-(8-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine

HRID 1945846
인쇄

반응식

HRID 1945846 반응식
Br[CH2:2][C:3]1[N:4]([CH3:28])[C:5]2[C:10]([N:11]=1)=[C:9]([N:12]1[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1)[N:8]=[C:7]([N:18]1[C:22]3[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=3[N:20]=[C:19]1[CH3:27])[N:6]=2.[CH:29]1([CH2:32][N:33]2[CH2:38][CH2:37][NH:36][CH2:35][CH2:34]2)[CH2:31][CH2:30]1>>[CH:29]1([CH2:32][N:33]2[CH2:38][CH2:37][N:36]([CH2:2][C:3]3[N:4]([CH3:28])[C:5]4[C:10]([N:11]=3)=[C:9]([N:12]3[CH2:17][CH2:16][O:15][CH2:14][CH2:13]3)[N:8]=[C:7]([N:18]3[C:22]5[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=5[N:20]=[C:19]3[CH3:27])[N:6]=4)[CH2:35][CH2:34]2)[CH2:31][CH2:30]1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 9658751-(Cyclopropylmethyl)piperazineHCID 596058124-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine

생성물 1

HCID 596057104-(8-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine

실험 절차

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with 1-(cyclopropylmethyl)piperazine via General Procedure E to give 23.5 mg of 277 following reverse phase purification. MS (Q1) 502.3 (M)+

후처리

  • customto give
  • custom23.5 mg of 277 following reverse phase purification
  • 출처 및 근거

    ORD 기록
    ord-488b13e4902c4556808cf5e13689542d
    출처 데이터셋
    uspto-grants-2013_03
    DOI
    10.6084/m9.figshare.5104873.v1
    특허 번호
    US08394796B2

    반응 노트

    이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트